Moderna’s COVID-19 vaccine is 90% effective after six months of taking second dose: Study
Moderna declared on Tuesday, that their vaccine is 90 per cent effective, six months after the person gets their second shot.
Moderna declared on Tuesday, that their vaccine was 90 per cent effective six months after the person gets their second shot.
To date, the company has produced approximately 132 million doses of Moderna Covid-19 vaccine globally. The company said in a statement that “The new results from a preclinical study from the company’s COVID-19 variant-specific booster vaccine candidates (mRNA-1272.351 and mRNA-1273.211) increase neutralizing titers (the concentration of antibodies) against SARS-CoV-2 variants of concern.”
The company further said that the vaccine efficacy starting two weeks following the second dose and based on the updated adjudicated cases remains consistent with prior updates, including greater than 90% against all cases of COVID-19, and greater than 95% against severe cases of COVID-19. The Hill reported that Moderna is working for its vaccine to be fully approved by the US, as it is only under emergency authorization under Food and Drug Administration, as quoted by a report of ANI.
Stephane Bancel, the chief executive officer of Moderna, told ANI– “The Moderna team continues to make important progress with its COVID-19 vaccine. We are looking forward to having clinical data from our variant-specific booster candidates, as well as clinical data from the phase 2/3 study of our COVID-19 Vaccine in adolescents.” The new preclinical data on their new variant-specific vaccines, candidates are giving them confidence that they can proactively address emerging variants. Moderna will make as many updates to their COVID-19 vaccine as necessary until the pandemic is under control.”
The study includes data from 900 coronavirus cases with most of the cases being severe. As reported by The Hill, along with the updated efficacy of the vaccine, Moderna is also working on its second phase for testing in adolescents. Moreover, the news outlet says there are 3,000 minors aged between 12 and 17, who are fully enrolled in Moderna’s trial and the company is working on enrolling children from 6 months to 11 years old.